When Gilead Sciences was sued by the federal government for $1 billion regarding alleged patent violations, the company turned to intellectual property litigators at Wilmer Cutler Pickering Hale and Dorr for its defense.

The case—the first time the government sued a pharmaceutical company for patent infringement—was closely watched by the industry because a loss for Gilead could have meant a disruption in the long history of pharmaceutical companies collaborating with the government to make drugs. But the team at Wilmer was able to pull off a win for the drug company in May.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]